• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Jonathan Silverberg Explains JAK/STAT Pathway Involvement in Atopic Dermatitis

Video

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses the involvement of the JAK/STAT pathway in the pathogenesis of atopic dermatitis.

JAK1 and in some cases JAK2 have been shown to play mediating roles in signaling various extracellular cytokines that contribute to the pathogenesis of atopic dermatitis, said Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology and director of clinical research and patch testing at George Washington University School of Medicine and Health Sciences.


Transcript

How is the JAK/STAT pathway involved in the pathogenesis and/or mediation of atopic dermatitis?

The JAK/STAT pathway is involved potentially in the pathogenesis of atopic dermatitis in several different ways. When we think about the various cytokines that have been implicated in atopic dermatitis, there are many. There's interleukin (IL)-13, IL-4, IL-31, TSLP [thymic stromal lymphopoietin], IL-22, etc. These are all extracellular cytokines, extracellular signals, that in order for them to work and have an effect intracellularly they have to bind to receptors and then something has to pass that signal into the cell. The JAKs, the Janus kinases, are those signals.

So, in particular, JAK1 and, to some extent, JAK2 play important roles in mediating the signals of those different cytokines that I just mentioned. The thought process is rather than just targeting a single cytokine, we could potentially block the signaling of multiple cytokines by blocking the JAKs from transducing those signals for the different cytokines.

Related Videos
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Debra Boyer, MD, MHPE, ATSF.
Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.